Literature DB >> 21813728

Predictors of breast density change after hormone therapy cessation: results from a randomized trial.

Sarah J Lowry1, Erin J Aiello Bowles, Melissa L Anderson, Diana S M Buist.   

Abstract

BACKGROUND: Postmenopausal hormone therapy cessation is associated with a decrease in mammographic density (MD), but it is unknown whether this effect is modified by woman-level characteristics. We investigated whether we could identify characteristics of women who were most likely to experience a decrease in MD due to hormone therapy cessation.
METHODS: Postmenopausal hormone therapy users with a prior screening mammogram (n = 1,168) were randomized to continue hormone therapy or to suspend hormone therapy for 1 month or 2 months before their next screening mammogram. We estimated relative risks (RR) and attributable risks with 95% CIs of a ≥7.5% decrease in percentage MD (%MD) versus no change associated with hormone therapy cessation, stratified by age, body mass index (BMI), parity, and other factors.
RESULTS: Hormone therapy cessation increased a woman's likelihood of experiencing a ≥7.5% decrease in %MD by 30% (95% CI = 1.03-1.7), but we found little evidence of effect modification by age, race, BMI, change in BMI, baseline %MD, parity, family history of breast cancer, hormone therapy type, or duration of hormone therapy use.
CONCLUSIONS: Woman-level factors do not appear to explain why some women experience a decrease in %MD following hormone therapy cessation and others do not. IMPACT: We were unable to identify subgroups of women who are more likely to experience a decrease in MD due to hormone therapy cessation; other factors, such as genetic factors, may be important determinants of hormone therapy-related changes in MD. ©2011 AACR

Entities:  

Mesh:

Year:  2011        PMID: 21813728      PMCID: PMC3189299          DOI: 10.1158/1055-9965.EPI-11-0629

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  8 in total

Review 1.  Breast tissue composition and susceptibility to breast cancer.

Authors:  Norman F Boyd; Lisa J Martin; Michael Bronskill; Martin J Yaffe; Neb Duric; Salomon Minkin
Journal:  J Natl Cancer Inst       Date:  2010-07-08       Impact factor: 13.506

2.  Factors associated with non-compliance with hormone therapy cessation before screening mammography.

Authors:  K M Newton; M L Anderson; S D Reed; E J A Bowles; D S M Buist
Journal:  Climacteric       Date:  2010-10-27       Impact factor: 3.005

Review 3.  Mammographic densities and breast cancer risk.

Authors:  N F Boyd; G A Lockwood; J W Byng; D L Tritchler; M J Yaffe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1998-12       Impact factor: 4.254

4.  Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.

Authors:  Anne McTiernan; Christopher F Martin; Jennifer D Peck; Aaron K Aragaki; Rowan T Chlebowski; Etta D Pisano; C Y Wang; Robert L Brunner; Karen C Johnson; JoAnn E Manson; Cora E Lewis; Jane M Kotchen; Barbara S Hulka
Journal:  J Natl Cancer Inst       Date:  2005-09-21       Impact factor: 13.506

5.  Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial.

Authors:  Anne McTiernan; Rowan T Chlebowski; Christopher Martin; Jennifer David Peck; Aaron Aragaki; Etta D Pisano; C Y Wang; Karen C Johnson; Joann E Manson; Robert B Wallace; Mara Z Vitolins; Gerardo Heiss
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

6.  Short-term hormone therapy suspension and mammography recall: a randomized trial.

Authors:  Diana S M Buist; Melissa L Anderson; Susan D Reed; Erin J Aiello Bowles; E Dawn Fitzgibbons; Juleann C Gandara; Deborah Seger; Katherine M Newton
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

7.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

Authors:  Rowan T Chlebowski; Susan L Hendrix; Robert D Langer; Marcia L Stefanick; Margery Gass; Dorothy Lane; Rebecca J Rodabough; Mary Ann Gilligan; Michele G Cyr; Cynthia A Thomson; Janardan Khandekar; Helen Petrovitch; Anne McTiernan
Journal:  JAMA       Date:  2003-06-25       Impact factor: 56.272

8.  Mammographic features and breast cancer risk: effects with time, age, and menopause status.

Authors:  C Byrne; C Schairer; J Wolfe; N Parekh; M Salane; L A Brinton; R Hoover; R Haile
Journal:  J Natl Cancer Inst       Date:  1995-11-01       Impact factor: 13.506

  8 in total
  2 in total

1.  Growth factor genes and change in mammographic density after stopping combined hormone therapy in the California Teachers Study.

Authors:  Eunjung Lee; Jianning Luo; Fredrick R Schumacher; David Van Den Berg; Anna H Wu; Daniel O Stram; Leslie Bernstein; Giske Ursin
Journal:  BMC Cancer       Date:  2018-11-06       Impact factor: 4.430

2.  Hormone metabolism pathway genes and mammographic density change after quitting estrogen and progestin combined hormone therapy in the California Teachers Study.

Authors:  Eunjung Lee; Jianning Luo; Yu-Chen Su; Juan Pablo Lewinger; Fredrick R Schumacher; David Van Den Berg; Anna H Wu; Leslie Bernstein; Giske Ursin
Journal:  Breast Cancer Res       Date:  2014-12-11       Impact factor: 8.408

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.